Publicaciones en las que colabora con Magdalena Salcedo Plaza (15)

2022

  1. Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation

    American Journal of Transplantation, Vol. 22, Núm. 6, pp. 1671-1682

2018

  1. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

  2. Prevalence and progression of chronic kidney disease after liver transplant: a prospective, real-life, observational, two-year multicenter study

    Revista Española de Enfermedades Digestivas, Vol. 110, Núm. 9, pp. 538-543

2017

  1. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation

    Journal of Hepatology, Vol. 67, Núm. 6, pp. 1168-1176

  2. Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study

    Transplant International, Vol. 30, Núm. 10, pp. 1041-1050

  3. Human immunodeficiency virus–infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study

    Liver Transplantation, Vol. 23, Núm. 5, pp. 645-651

  4. Real-world multicenter experience of immunosuppression minimization among 661 liver transplant recipients

    Annals of Transplantation, Vol. 22, pp. 265-275

  5. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry

    Hepatology, Vol. 65, Núm. 6, pp. 1810-1822

2016

  1. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

  2. Impact of cytomegalovirus infection on severe hepatitis c recurrence in patients undergoing liver transplantation

    Transplantation, Vol. 100, Núm. 3, pp. 593-599

2015

  1. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey

    Clinical Microbiology and Infection, Vol. 21, Núm. 6, pp. 604.e1-604.e9

  2. Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain

    Liver Transplantation, Vol. 21, Núm. 8, pp. 1056-1065

  3. V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante

    Cirugia Espanola, Vol. 93, Núm. 10, pp. 619-637

2012

  1. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation

    Liver Transplantation, Vol. 18, Núm. 1, pp. 45-52

2011

  1. Cyclosporine A-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: A large multicenter cohort study

    Transplantation, Vol. 92, Núm. 3, pp. 334-340